Project Grant R21CA291288
Award Date 7/9/24
Completion Date 6/30/26
Dollars Obligated $411K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $216,013 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Wisconsin-Madison to investigate the effect of caspases and anti-viral responses on Kaposi's sarcoma-associated herpesvirus (KSHV) tumorigenesis. The research project aims to discover strategies to block KSHV reactivation and its associated pro-tumor activities as a starting point for developing new targeted therapies for Kaposi's sarcoma, a major...
- The National Cancer Institute (NCI) awarded a $432,098 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Fred Hutchinson Cancer Center, also known as the Seattle Cancer Care Alliance, to support research on HIV persistence and treatment response in Kaposi Sarcoma (KS). The research aims to identify factors that contribute to the differential outcomes observed among participants in the HIPPOS KS cohort study in Uganda, with the goal of informing the design of more...
- This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
- This is a Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to the Fred Hutchinson Cancer Center in Seattle, Washington. The $4,234,248 award, which runs from September 2025 through August 2029, supports comprehensive research to characterize the T-cell immune response to Kaposi Sarcoma Herpesvirus (KSHV). The goal is to enable the development of specific immunotherapies for KSHV-associated diseases, which include...
- The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $1,349,322 Project Grant to the University of Pittsburgh to study how the Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolic pathways, specifically the methionine/S-adenosylmethionine (SAM) cycle, to maximize viral latent and lytic infections. The project aims to identify KSHV-regulated methyltransferase METTL16-specific N6-methyladenosine (m6A) marks, delineate the mechanisms by which the...
- This $877,104 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the molecular mechanisms of Kaposi's Sarcoma-associated Herpesvirus (KSHV) infection and persistence. The grant funds computational analyses of bulk and single-cell RNA sequencing data from KSHV-infected monocytes, macrophages, and B cells to understand how the virus impacts these...
- This Project Grant award of $188,169 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, Davis (UC Davis) supports the development of a gene therapy vector using the adeno-associated virus (AAV) system to target Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The goal is to selectively express therapeutic genes, such as the thymidine kinase (TK)/ganciclovir (GCV) system, in KSHV-infected tumor cells that express...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $476,754 to Barnard College to study genome-wide chromatin structure and function in Kaposi sarcoma tissue. The project aims to identify virus-associated host enhancers and regulated genes, as well as host super-enhancers, in Kaposi sarcoma tissue samples obtained from the AIDS and Cancer Specimen Resource. Multiome single-cell ATAC-seq and single-cell RNA-seq experiments will be...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to determine the role of macrophage migration inhibitory factor (MIF) signaling activation in Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies. The $306,000 grant, awarded from August 1, 2025 to July 31, 2027, will be used by the University of Arkansas for Medical Sciences to: 1) investigate...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $4,857,475.00 to the University of California, Los Angeles (UCLA) to develop a strategically engineered multi-antigen vaccine against Kaposi's Sarcoma-associated Herpesvirus (KSHV), also known as Human Herpesvirus-8 (HHV-8). The objective is to create a vaccine that can effectively prime the immune system to generate robust and reliable antibody and T-cell mediated...